Endeavor BioMedicines

Endeavor BioMedicines is developing new therapies targeting the underlying causes of pulmonary fibrosis. The company is advancing taladegib, a small molecule Hedgehog signaling pathway inhibitor, which is currently under investigation for the treatment of idiopathic pulmonary fibrosis (IPF). By addressing the root cause of this disease, taladegib has the potential to halt or even reverse IPF.